We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients.
- Authors
Munzone, Elisabetta; Fabi, Alessandra; Buono, Giuseppe; Caputo, Roberta; Montagna, Emilia; Negri, Mara; Nuzzo, Francesco; Palazzo, Antonella; Paris, Ida; Conti, Luca; Baggi, Anna; Franzini, Jean Marie; De Laurentiis, Michelino
- Abstract
Background: This study evaluated the impact of using the subcutaneous fixed-dose combination of pertuzumab + trastuzumab (PH FDC SC) compared with intravenous pertuzumab followed by intravenous trastuzumab (P+T IV) in HER2+ breast cancer patients. Methods: Data from three Italian hospitals were collected to assess the organizational and economic benefits of PH FDC SC versus P+T IV on (i) patient pathway time, (ii) personnel time, (iii) direct costs and (iv) recoverable efficiency for the hospital, and (v) social impact for patient and caregivers. Data from hospitals were averaged when calculating results. Results: PH FDC SC induced a reduction in patients' pathway time (ΔIV→SC: −59 min), driven by the administration phase (ΔIV→SC: −89 min); personnel time (ΔIV→SC: −17 min /patient), and direct costs for hospitals (ΔIV→SC: −125.95€/patient). A complete switch to PH FDC SC would also induce potential productivity gains in terms of additional oncological therapies administered by the hospital (ΔIV→SC: +532/year), together with decreased yearly social indirect costs for patients (−13.3%) and caregivers (−13.5%). Conclusion: Overall, PH FDC SC demonstrated potential economic and organizational advantages for hospitals and patients compared with P+T IV, even though patients treated subcutaneously experienced longer waits between activities, indicating the need for optimized organizational choices.
- Subjects
ITALY; MEDICATION error prevention; THERAPEUTIC use of monoclonal antibodies; INTRAVENOUS therapy equipment; THERAPEUTIC use of antineoplastic agents; LENGTH of stay in hospitals; INTRAVENOUS therapy; ACADEMIC medical centers; CAREGIVERS; SCIENTIFIC observation; TIME; CROSS-sectional method; ANTINEOPLASTIC agents; MONOCLONAL antibodies; MEDICAL care costs; PATIENT satisfaction; CANCER patients; PATIENTS' attitudes; COMPARATIVE studies; ORGANIZATIONAL effectiveness; QUESTIONNAIRES; ECONOMIC aspects of diseases; BREAST tumors; SUBCUTANEOUS injections; TRANSPORTATION
- Publication
Drugs & Therapy Perspectives, 2023, Vol 39, Issue 12, p432
- ISSN
1172-0360
- Publication type
Article
- DOI
10.1007/s40267-023-01038-5